Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...

Needham & Company LLC reiterated their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report released on Friday,Benzinga reports. Several other equities ...

UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $154 from the previous $176, while continuing to recommend the stock as a Buy. Currently trading at $118 ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...

Shares of Neurocrine Biosciences Inc. plummeted 19 percent week-on-week to close Friday’s trading at $122.62 each as ...

Neurocrine Biosciences Inc. shares dived 18.53 percent on Friday, a third consecutive day, as investors digested the ...

One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...